Literature DB >> 2775614

Comparison of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients.

C P Denaro1, P J Ravenscroft.   

Abstract

1. Individual pharmacokinetic parameters and predicted steady-state serum concentrations of aminoglycosides were calculated by Sawchuck-Zaske (SZ) and Bayesian methods. 2. Predicted concentrations were compared with observed steady-state concentrations for 36 seriously ill patients with systemic infections. Four aminoglycoside concentrations were used for the SZ method. Differing numbers of serum aminoglycoside samples were used in the Bayesian parameter estimation: one sample Bayesian used one post-infusion concentration, two sample Bayesian used a trough plus one post-infusion concentrations and four sample Bayesian used a trough plus three post-infusion concentrations. 3. 79% of the SZ predictions were with +/- 2 mg l-1 of the observed peak concentrations, and 72% of the two sample Bayesian predictions were within the same range. 82% of SZ and the two sample Bayesian predictions were within +/- 1 mg l-1 of the observed trough concentrations. 4. A confidence interval comparison of estimated pharmacokinetic parameters and precision for the predicted concentrations showed no important differences between the SZ and the two sample Bayesian. The four sample Bayesian was the most precise method. 5. We conclude that the Bayesian forecasting method utilizing a trough plus one post-infusion concentrations is as useful as the SZ method which requires three to four serum concentrations in individualizing aminoglycoside therapy for seriously ill patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2775614      PMCID: PMC1379968          DOI: 10.1111/j.1365-2125.1989.tb03503.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations.

Authors:  L B Sheiner; H Halkin; C Peck; B Rosenberg; K L Melmon
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

2.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients.

Authors:  R J Sawchuk; D E Zaske
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

3.  Gentamicin serum concentrations: pharmacokinetic predictions.

Authors:  J H Hull; F A Sarubbi
Journal:  Ann Intern Med       Date:  1976-08       Impact factor: 25.391

4.  Modelling of individual pharmacokinetics for computer-aided drug dosage.

Authors:  L B Sheiner; B Rosenberg; K L Melmon
Journal:  Comput Biomed Res       Date:  1972-10

5.  Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin.

Authors:  G G Jackson; L J Riff
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

6.  Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever.

Authors:  J E Pennington; D C Dale; H Y Reynolds; J D MacLowry
Journal:  J Infect Dis       Date:  1975-09       Impact factor: 5.226

7.  Pharmacokinetics of gentamicin in children and adults.

Authors:  G R Siber; P Echeverria; A L Smith; J W Paisley; D H Smith
Journal:  J Infect Dis       Date:  1975-12       Impact factor: 5.226

8.  Predictability of blood levels of gentamicin in man.

Authors:  M Barza; R B Brown; D Shen; M Gibaldi; L Weinstein
Journal:  J Infect Dis       Date:  1975-08       Impact factor: 5.226

9.  Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis.

Authors:  P Noone; T M Parsons; J R Pattison; R C Slack; D Garfield-Davies; K Hughes
Journal:  Br Med J       Date:  1974-03-16

10.  Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients.

Authors:  C P Denaro; P J Ravenscroft
Journal:  Aust N Z J Med       Date:  1987-10
View more
  5 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.

Authors:  Stefanie Hennig; Franziska Holthouse; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

3.  Aminoglycoside forecasting in neutropenic patients with cancer.

Authors:  J L Kosirog; R M Rospond; C Destache; P Hall
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

Review 4.  Aminoglycosides--50 years on.

Authors:  E J Begg; M L Barclay
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

Review 5.  Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.

Authors:  Alfonso Iorio; Andrea N Edginton; Victor Blanchette; Jan Blatny; Ana Boban; Marjon Cnossen; Peter Collins; Stacy E Croteau; Katheljin Fischer; Daniel P Hart; Shinya Ito; Joan Korth-Bradley; Stefan Lethagen; David Lillicrap; Mike Makris; Ron Mathôt; Massimo Morfini; Ellis J Neufeld; Jeffrey Spears
Journal:  Res Pract Thromb Haemost       Date:  2018-05-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.